These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29854676)

  • 1. Role of Red Cell Distribution Width in the Relationship between Clinical Outcomes and Anticoagulation Response in Patients with Atrial Fibrillation.
    Lee KH; Cho JG; Park HW; Yoon NS; Jeong HK; Lee N
    Chonnam Med J; 2018 May; 54(2):113-120. PubMed ID: 29854676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red cell distribution width as a novel predictor for clinical outcomes in patients with paroxysmal atrial fibrillation.
    Lee KH; Park HW; Cho JG; Yoon NS; Kim SS; Kim MR; Kim MC; Cho KH; Kim HK; Kim CH; Kim KH; Jun SJ; Kim WJ; Lee KJ; Jeong HC; Cho JY; Park KH; Sim Ds; Yoon HJ; Kim KH; Hong YJ; Kim JH; Ahn Y; Jeong MH; Park JC
    Europace; 2015 Oct; 17 Suppl 2():ii83-8. PubMed ID: 26842121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Anticoagulation Intensity in Korean Patients with Atrial Fibrillation: Is It Different from Western Population?
    Lee KH; Cho JG; Lee N; Cho KH; Jeong HK; Park H; Kim Y; Cho JY; Kim MC; Sim DS; Yoon HJ; Yoon N; Kim KH; Hong YJ; Park HW; Ahn Y; Jeong MH; Park JC
    Korean Circ J; 2020 Feb; 50(2):163-175. PubMed ID: 31642215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
    Dallalzadeh LO; Go AS; Chang Y; Borowsky LH; Fang MC; Singer DE
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27451456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.
    Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F
    Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin.
    Senoo K; Lip GY
    Stroke; 2016 Jun; 47(6):1665-8. PubMed ID: 27125527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
    Fanola CL; Ruff CT; Murphy SA; Jin J; Duggal A; Babilonia NA; Sritara P; Mercuri MF; Kamphuisen PW; Antman EM; Braunwald E; Giugliano RP
    J Am Heart Assoc; 2018 Aug; 7(16):e008987. PubMed ID: 30369307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.
    Szummer K; Gasparini A; Eliasson S; Ärnlöv J; Qureshi AR; Bárány P; Evans M; Friberg L; Carrero JJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28249846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of Red Cells Distribution Width to Predict Worse Outcomes in Patients With Atrial Fibrillation.
    Malavasi VL; Proietti M; Spagni S; Valenti AC; Battista A; Pettorelli D; Colella J; Vitolo M; Lip GY; Boriani G
    Am J Cardiol; 2019 Nov; 124(10):1561-1567. PubMed ID: 31521256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between elevated red cell distribution width and long-term outcomes among patients with atrial fibrillation.
    Wan H; Yang Y; Zhu J; Huang B; Wang J; Wu S; Shao X; Zhang H
    Clin Biochem; 2015 Aug; 48(12):762-7. PubMed ID: 26054582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of increased time in the therapeutic range on atrial fibrillation outcomes within a centralized anticoagulation service.
    Phelps E; Delate T; Witt DM; Shaw PB; McCool KH; Clark NP
    Thromb Res; 2018 Mar; 163():54-59. PubMed ID: 29407629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
    Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
    Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB;
    J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry.
    Lehto M; Niiranen J; Korhonen P; Mehtälä J; Khanfir H; Hoti F; Lassila R; Raatikainen P
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):657-665. PubMed ID: 28317274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.
    Van Spall HG; Wallentin L; Yusuf S; Eikelboom JW; Nieuwlaat R; Yang S; Kabali C; Reilly PA; Ezekowitz MD; Connolly SJ
    Circulation; 2012 Nov; 126(19):2309-16. PubMed ID: 23027801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials.
    Proietti M; Lip GYH
    Int J Cardiol; 2018 Feb; 252():96-100. PubMed ID: 29249444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry.
    Proietti M; Airaksinen KEJ; Rubboli A; Schlitt A; Kiviniemi T; Karjalainen PP; Lip GY;
    Am Heart J; 2017 Aug; 190():86-93. PubMed ID: 28760217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.